

9th August, 2019

Scrip Code: **524816**

Natco Pharma Limited Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243

CIN: L24230TG1981PLC003201, www.natcopharma.co.in

Corporate Relationship Dept. The BSE Ltd. Dalal Street, Fort Mumbai 400 001.

Manager - Listing National Stock Exchange of India Ltd "Exchange Plaza", Bandra-Kurla Complex Bandra (E) Mumbai 400 051.

Scrip Code: **NATCOPHARM**

Dear Sir,

Sub: - Outcome of Board Meeting

We would like to inform you that the Board of Directors of the Company at their meeting held today have considered and approved the following along with other items of business:

- 1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2019 prepared under Indian Accounting Standards (IND-AS) and as per Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") along with Limited Review Report of the Statutory Auditors. Please find enclosed a copy of the same along with Press Release.
- 2. Declaration of interim dividend of Rs.1.25 ps. per equity share of Rs.2/- each for the financial year 2019-20. The date for taking a record of its shareholders eligible for the purpose of payment of interim dividend i.e. Record date is fixed for 23rd August, 2019. The said interim dividend pay-by-date is on or before 29th August, 2019.
- 3. The Board of Directors have approved to make the following investments and authorized Mr. V.C. Nannapaneni, Chairman and Managing Director and Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer to finalise the terms and conditions of the proposed investments not exceeding:
 - a) Rs.5,00,00,000/- (Rupees Five Crores only) in OMRV Hospitals Private Limited.
 - b) US\$ 2,50,000/- (US Dollars Two Lakhs Fifty Thousand only) in AACT, Inc., USA

The disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the aforesaid investments will be given to the Stock Exchanges at the time of making investment by the Company.

We are also updating the financial results on the website of the Company.

Meeting commenced at 10.30 a.m. and concluded at 2.00 p.m.

This is for your information and records.

Thanking you, Yours faithfully, For NATCO Pharma Limited

MANdrayana M. Adinarayana

Company Secretary & Vice President (Legal & Corp. Affairs)

Encl: as above